WO2008075213A2 - Lateral flow assay device - Google Patents
Lateral flow assay device Download PDFInfo
- Publication number
- WO2008075213A2 WO2008075213A2 PCT/IB2007/053381 IB2007053381W WO2008075213A2 WO 2008075213 A2 WO2008075213 A2 WO 2008075213A2 IB 2007053381 W IB2007053381 W IB 2007053381W WO 2008075213 A2 WO2008075213 A2 WO 2008075213A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- membrane
- storage section
- meter
- assay device
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150412—Pointed piercing elements, e.g. needles, lancets for piercing the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150534—Design of protective means for piercing elements for preventing accidental needle sticks, e.g. shields, caps, protectors, axially extensible sleeves, pivotable protective sleeves
- A61B5/150694—Procedure for removing protection means at the time of piercing
- A61B5/150717—Procedure for removing protection means at the time of piercing manually removed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150801—Means for facilitating use, e.g. by people with impaired vision; means for indicating when used correctly or incorrectly; means for alarming
- A61B5/150824—Means for facilitating use, e.g. by people with impaired vision; means for indicating when used correctly or incorrectly; means for alarming by visual feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15101—Details
- A61B5/15103—Piercing procedure
- A61B5/15105—Purely manual piercing, i.e. the user pierces the skin without the assistance of any driving means or driving devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15101—Details
- A61B5/15103—Piercing procedure
- A61B5/15107—Piercing being assisted by a triggering mechanism
- A61B5/15113—Manually triggered, i.e. the triggering requires a deliberate action by the user such as pressing a drive button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15101—Details
- A61B5/15115—Driving means for propelling the piercing element to pierce the skin, e.g. comprising mechanisms based on shape memory alloys, magnetism, solenoids, piezoelectric effect, biased elements, resilient elements, vacuum or compressed fluids
- A61B5/15117—Driving means for propelling the piercing element to pierce the skin, e.g. comprising mechanisms based on shape memory alloys, magnetism, solenoids, piezoelectric effect, biased elements, resilient elements, vacuum or compressed fluids comprising biased elements, resilient elements or a spring, e.g. a helical spring, leaf spring, or elastic strap
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15186—Devices loaded with a single lancet, i.e. a single lancet with or without a casing is loaded into a reusable drive device and then discarded after use; drive devices reloadable for multiple use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/151—Devices specially adapted for taking samples of capillary blood, e.g. by lancets, needles or blades
- A61B5/15186—Devices loaded with a single lancet, i.e. a single lancet with or without a casing is loaded into a reusable drive device and then discarded after use; drive devices reloadable for multiple use
- A61B5/15188—Constructional features of reusable driving devices
- A61B5/1519—Constructional features of reusable driving devices comprising driving means, e.g. a spring, for propelling the piercing unit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0605—Metering of fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/16—Reagents, handling or storing thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0672—Integrated piercing tool
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
- B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/06—Valves, specific forms thereof
- B01L2400/0677—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers
- B01L2400/0683—Valves, specific forms thereof phase change valves; Meltable, freezing, dissolvable plugs; Destructible barriers mechanically breaking a wall or membrane within a channel or chamber
Definitions
- Test strips are often used for qualitative and quantitative analysis of blood components or other fluids. With the lateral flow method, a spatial separation is defined in the strips between the sample application area and detection zone. Most conventional lateral flow strips are designed for test samples that are readily available in large quantities (e.g., urine). However, when the test sample is blood, the collection of a large sample may cause undue pain to the patient. Thus, one technique that has been utilized to accommodate smaller test sample volumes is to "spot" the sample directly on the membrane surface of the test strip. Thereafter, a diluent is used to wash away the test sample and carry it to the detection zone. Unfortunately, variations associated with sample transfer and diffusion of the sample to the membrane result in a flow that is largely uncontrolled and uneven before reaching the detection zone.
- a diagnostic lateral flow assay device for detecting the presence of an analyte within a test sample.
- the device and associated method of use are particularly well suited for use with relatively small blood samples of generally less than 10 microliters, and aspects of the invention will be described herein by reference to a blood sampling device and method. It should be appreciated, however, that this is for illustrative purposes only, and that the device is not limited to blood sampling.
- the lateral flow assay device has a housing and a test strip within the housing.
- the test strip includes a membrane having a collection region that receives the test sample, and a detection region.
- a blood sample meter is provided having a first end for absorption of a blood sample, and may include a filter section adjacent the first end that filters red blood cell components from the blood sample.
- a storage section adjacent the filtering section receives the plasma or serum from the filtering section.
- An opening in the housing is sized for insertion of the sample meter into the housing such that the storage section of the sample meter is disposed adjacent to the collection region of membrane.
- the assay device includes an internal mechanism configured to isolate a specific section of the sample meter (e.g., by scoring and scraping) so that only a well-defined section of the test meter is presented to the collection region of the test strip.
- This defined section may be, for example, a 5 mm length of the sample meter storage section. This section is saturated with the sample fluid and thus, based on the absorbent capacity of the sample meter, contains a precisely determined amount of the sample fluid.
- the defined length of storage section is brought into fluid communication with the collection region of the membrane (by direct contact or through an intermediary member) and the filtered plasma or serum is transferred from the defined length of storage section to the collection region of the membrane for subsequent migration to the detection region.
- This transfer of plasma or serum typically would occur through simple capillary action, but may also be caused to occur through other means.
- a diluent may be supplied to the collection region to facilitate flow of the test sample from the collection region to the detection region of the membrane.
- the sample meter includes a separation membrane material attached to a storage membrane with an overlap between the membranes.
- the separation membrane serves to drawn in the blood sample (e.g., through capillary action) and separate out red blood cell components.
- the resulting filtered plasma or serum is transferred to the storage membrane.
- the sample meter is not limited by dimensions or shape.
- the separation membrane may have a length of between about 3 to about 12 mm, and the overlap region between the separation and storage membranes may be between about 1 mm to about 3 mm.
- the storage membrane may have a length of between about 10 mm to about 40 mm.
- the sample meter is an elongated member having a width of between about 1 mm to about 5 mm, and a length of between about 25 mm to about 40 mm.
- the separation membrane may extend to the first end of the sample meter, and the storage membrane may extend to an opposite second end of the sample meter.
- the assay device may incorporate an internal source of diluent that is applied so as to flow to the collection region subsequent to insertion of the sample meter into the assay housing.
- the diluent may be stored in a rupturable container or pouch within the housing. Means may be provided for rupturing or otherwise breaching this container subsequent to or coinciding with insertion and scraping of the sample meter within the housing.
- a push-button, slide mechanism, or other manually actuated device may be configured with the assay housing whereby, upon actuation of the mechanism, a point or blade configured on the mechanism pierces the container causing the diluent to flow to the collection region of the membrane.
- the mechanism may also serve to compress the container so as to force the diluent therefrom towards the direction of the membrane.
- This mechanism may be configured to work in conjunction with the sample meter scraping mechanism, or may be a separate mechanism.
- the scraping mechanism may be actuated by a first manual device (e.g. push-button or slide) with the diluent releasing mechanism actuated by a separate manual device.
- the two mechanisms may be actuated by a single manual device. It should be appreciated that any number of manually actuated devices may be readily configured by those skilled in the art for this purpose, and all such devices are within the scope and spirit of the invention.
- the diluent may be supplied from an external source, with the assay housing configured for fluid communication with this external source.
- the diluent may be supplied in a disposable, squeezable container having a nozzle that communicates with a port on the assay housing. This port may be configured to internally direct the diluent directly to the collection region of the membrane.
- the invention also encompasses all variations of methods of using the blood sample meters and associated assay devices, as described above.
- Figure 1 is a perspective view of a lateral flow assay device that incorporates aspects of the present invention.
- Figures 2A and 2B are a top perspective and cross-sectional view, respectively, of a sample meter.
- Figures 3A and 3B are cross-sectional operational views of an embodiment of a scraping mechanism that may be used in an assay device according to the invention.
- Figures 4A and 4B are additional cross-sectional views of a scraping mechanism that may be used in an assay device according to the invention.
- Figure 5 is a perspective view of a tray component used to retain the test strip in particular embodiment of the invention.
- Figure 6 is a perspective view of a sample meter that has been scored and scraped with a device according to aspects of the invention.
- Figure 7 is a cross-sectional view of an alternative embodiment of an assay device according to the invention.
- FIG. 8 is a top view of still another embodiment of an assay device according to the invention. Repeat use of reference characters in the present specification and drawings is intended to represent same or analogous features or elements of the invention.
- analytes generally refers to a substance to be detected.
- analytes may include antigenic substances, haptens, antibodies, and combinations thereof.
- Analytes include, but are not limited to, toxins, organic compounds, proteins, peptides, microorganisms, amino acids, nucleic acids, hormones, steroids, vitamins, drugs (including those administered for therapeutic purposes as well as those administered for illicit purposes), drug intermediaries or byproducts, bacteria, virus particles and metabolites of or antibodies to any of the above substances.
- analytes include ferritin; creatinine kinase MB (CK-MB); digoxin; phenytoin; phenobarbitol; carbamazepine; vancomycin; gentamycin; theophylline; valproic acid; quinidine; luteinizing hormone (LH); follicle stimulating hormone (FSH); estradiol, progesterone; C-reactive protein; lipocalins; IgE antibodies; cytokines; vitamin B2 micro-globulin; glycated hemoglobin (GIy.
- ferritin creatinine kinase MB
- CK-MB creatinine kinase MB
- digoxin phenytoin
- phenobarbitol carbamazepine
- vancomycin gentamycin
- theophylline valproic acid
- quinidine quinidine
- LH luteinizing hormone
- FSH follicle stimulating hormone
- Hb Cortisol; digitoxin; N- acetylprocainamide (NAPA); procainamide; antibodies to rubella, such as rubella- IgG and rubella IgM; antibodies to toxoplasmosis, such as toxoplasmosis IgG (Toxo-lgG) and toxoplasmosis IgM (Toxo-lgM); testosterone; salicylates; acetaminophen; hepatitis B virus surface antigen (HBsAg); antibodies to hepatitis B core antigen, such as anti-hepatitis B core antigen IgG and IgM (Anti-HBC); human immune deficiency virus 1 and 2 (HIV 1 and 2); human T-cell leukemia virus 1 and 2 (HTLV); hepatitis B e antigen (HBeAg); antibodies to hepatitis B e antigen (Anti-HBe); influenza virus; thyroid stimulating hormone (TSH); thyroxine (T
- Drugs of abuse and controlled substances include, but are not intended to be limited to, amphetamine; methamphetamine; barbiturates, such as amobarbital, secobarbital, pentobarbital, phenobarbital, and barbital; benzodiazepines, such as librium and Valium; cannabinoids, such as hashish and marijuana; ***e; fentanyl; LSD; methaqualone; opiates, such as heroin, morphine, codeine, hydromorphone, hydrocodone, methadone, oxycodone, oxymorphone and opium; phencyclidine; and propoxyhene.
- Other potential analytes may be described in U.S. Patent Nos. 6,436,651 to Everhart, et al. and 4,366,241 to Tom et al.
- test sample generally refers to a biological material suspected of containing the analyte.
- the test sample may be derived from any biological source, such as a physiological fluid, including, blood, interstitial fluid, saliva, ocular lens fluid, cerebral spinal fluid, sweat, urine, milk, ascites fluid, mucous, nasal fluid, sputum, synovial fluid, peritoneal fluid, vaginal fluid, menses, amniotic fluid, semen, and so forth.
- physiological fluids other liquid samples may be used such as water, food products, and so forth, for the performance of environmental or food production assays.
- a solid material suspected of containing the analyte may be used as the test sample.
- the test sample may be used directly as obtained from the biological source or following a pretreatment to modify the character of the sample.
- pretreatment may include preparing plasma from blood, diluting viscous fluids, and so forth.
- Methods of pretreatment may also involve filtration, precipitation, dilution, distillation, mixing, concentration, inactivation of interfering components, the addition of reagents, lysing, etc.
- it may also be beneficial to modify a solid test sample to form a liquid medium or to release the analyte.
- the present invention is directed generally to a diagnostic method and device for detecting the presence of an analyte within a blood test sample.
- the device and associated method of use are particularly well suited for use with relatively small blood samples of generally less than 10 microliters.
- the device is embodied in a particular embodiment as a lateral flow assay device 10 having a housing 12.
- the housing may include multiple components, such as an upper member 14 attached to a bottom member 16.
- the particular shape and construction of the housing 12 is not a limiting feature of the invention, and may be aesthetically pleasing configuration.
- the device 10 may include a lancet 11 configured at one end thereof to provide the user with a means to draw a blood sample.
- the lancet 11 may include any manner of spring-loaded or stationary needle that is protected by a removable cover 19 prior to use. The needle is used to pierce the user's skin to provide the desired blood sample. It should be appreciated that the lancet 11 is an optional feature, and that the blood sample may be drawn by any conventional means or separate device. Additionally, a lancet would not be needed for applications that do not involve a blood sample.
- the housing 12 may include a first window or viewing port 13 that indicates a "sample ready" condition of a sample meter 100 that is inserted into the device for analysis.
- This feature may be desired in that it informs the user when the test is ready to be conducted.
- Various means may be used to indicate the "ready” state.
- dye chemistry may be used wherein a water soluble dye or coloring agent is applied to a section of the sample meter (i.e., at the end of the blood separation membrane, as discussed below). When the serum/plasma has migrated through the dye spot, the dye is "activated” and gives a visible indication to the user that the sample is ready for testing.
- the housing may also include any manner of window or viewing port 15 to indicate the results of the test.
- this window 15 may be disposed over a portion of a test strip 18 within the housing 12 that gives a visible "positive” or “negative” indication (e.g., by color change, line formation, graphics, and so forth) after reacting with the serum/plasma transferred from the sample meter 100.
- This test strip 18 is discussed in greater detail below, but includes a reactive membrane 20 having a detection region 31 and a collection region 30, as described in greater detail below.
- the window 15 may display results of an electronic analysis of the sample. It should be appreciated that the device 10 is not limited by the manner in which the results are displayed to the user.
- an exemplary sample meter 100 having a first end 102 for absorption of a test sample, such as blood, an opposite end 104, a filter section 106 adjacent the first end 102 that filters red blood cell components from the blood sample, and a storage section 108 adjacent the filtering section 106 that receives the plasma or serum from the filtering section 106.
- An opening 17 in the housing 12, for example in a side of the housing, is sized for insertion of the sample meter 100 into the housing 12 such that the storage section 108 of the sample meter 100 is disposed adjacent to the collection region 30 of membrane 20.
- the storage section 108 is brought into fluid communication with the collection region 30 of the membrane 20 (by direct contact or through an intermediary member) and the filtered plasma or serum is transferred from the storage section 108 to the collection region 30 of the membrane 20 for subsequent migration to the detection region 31.
- a diluent may be supplied to the collection region 30 to facilitate flow of the test sample from the collection region 30 to the detection region 31.
- the combination of the sample meter 100 and test strip 18 (with membrane 20) is particularly effective for embodiments in which the blood test sample has a relatively low volume, such as less than about 10 microliters, in some embodiments less than about 5 microliters, and in some embodiments, between about 1 and about 3 microliters.
- a relatively low volume such as less than about 10 microliters, in some embodiments less than about 5 microliters, and in some embodiments, between about 1 and about 3 microliters.
- whole blood drops obtained from patients with a lancet from low-pain areas having reduced nerve endings as compared to a fingertip, such as the forearm, thigh, or other alternate sites may have a volume of less than about 5 microliters.
- the device and method of the present invention is effective in separating red blood cell components and providing a filtered test sample of plasma or serum that may be accurately analyzed for the presence of an analyte using lateral flow detection techniques.
- the membrane 20 may be made from any of a variety of materials through which the test sample is capable of passing.
- the membrane 20 may be formed from natural, synthetic, or naturally occurring materials that are synthetically modified, such as polysaccharides (e.g., cellulose materials such as paper and cellulose derivatives, such as cellulose acetate and nitrocellulose); polyether sulfone; polyethylene; nylon; polyvinylidene fluoride (PVDF); polyester; polypropylene; silica; inorganic materials, such as deactivated alumina, diatomaceous earth, MgSO 4 , or other inorganic finely divided material uniformly dispersed in a porous polymer matrix, with polymers such as vinyl chloride, vinyl chloride-propylene copolymer, and vinyl chloride-vinyl acetate copolymer; cloth, both naturally occurring (e.g., cotton) and synthetic (e.g., nylon or rayon); porous gels, such as silica gel, agarose, dextran, and gelatin; polymeric films, such as polyacrylamide; and so forth.
- polysaccharides e
- Particularly desired materials for forming the membrane 20 include polymeric materials, such as nitrocellulose, polyether sulfone, polyethylene, nylon, polyvinylidene fluoride, polyester, and polypropylene.
- nitrocellulose refers to nitric acid esters of cellulose, which may be nitrocellulose alone, or a mixed ester of nitric acid and other acids, such as aliphatic carboxylic acids having from 1 to 7 carbon atoms.
- the size and shape of the test strip may generally vary as is readily recognized by those skilled in the art.
- the test strip 18 may have a length of from about 10 to about 100 millimeters, in some embodiments from about 20 to about 80 millimeters, and in some embodiments, from about 40 to about 60 millimeters.
- the width of the strip 18 may also range from about 0.5 to about 20 millimeters, in some embodiments from about 1 to about 15 millimeters, and in some embodiments, from about 2 to about 10 millimeters.
- the thickness of the membrane 20 may be small enough to allow transmission- based detection.
- the membrane may have a thickness less than about 500 micrometers, in some embodiments less than about 250 micrometers, and in some embodiments, less than about 150 micrometers.
- the test strip 18 includes a support 21 for the membrane 20.
- the support 21 may be positioned directly adjacent to the membrane 20 as shown in the various figures, or one or more intervening layers may be positioned between the membrane 20 and the support 21.
- the support 21 may generally be formed from any material able to carry the membrane 20.
- the support 21 may be formed from a material that is transmissive to light, such as transparent or optically diffuse (e.g., transluscent) materials.
- transparent or optically diffuse e.g., transluscent
- it is generally desired that the support 21 is liquid-impermeable so that fluid flowing through the membrane 20 does not leak through the support 21.
- suitable materials for the support include, but are not limited to, glass; polymeric materials, such as polystyrene, polypropylene, polyester (e.g., Mylar® film), polybutadiene, polyvinylchloride, polyamide, polycarbonate, epoxides, methacrylates, and polymelamine; and so forth.
- polymeric materials such as polystyrene, polypropylene, polyester (e.g., Mylar® film), polybutadiene, polyvinylchloride, polyamide, polycarbonate, epoxides, methacrylates, and polymelamine; and so forth.
- the support 21 is generally selected to have a certain minimum thickness. Likewise, the thickness of the support 21 is typically not so large as to adversely affect its optical properties. Thus, for example, the support 21 may have a thickness that ranges from about 100 to about 5,000 micrometers, in some embodiments from about 150 to about 2,000 micrometers, and in some embodiments, from about 250 to about 1 ,000 micrometers. For instance, one suitable membrane having a thickness of about 125 micrometers may be obtained from Millipore Corp. of Bedford, Massachusetts under the name "SHF180UB25.” The membrane 20 may be cast onto the support 21 , wherein the resulting laminate may be die-cut to the desired size and shape.
- the membrane 20 may simply be laminated to the support 21 with, for example, an adhesive.
- a membrane e.g., nitrocellulose or nylon
- An adhesive is used to bind the membrane to the Mylar® film, such as a pressure-sensitive adhesive.
- Laminate structures of this type are believed to be commercially available from Millipore Corp. of Bedford, Massachusetts. Still other examples of suitable laminate assay device structures are described in U.S. Patent No. 5,075,077 to Durlev, III, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
- the device 10 may also contain an absorbent pad (not shown) within the housing 12 positioned adjacent to or near an end of the membrane 20. The absorbent pad generally receives fluid that has migrated through the entire membrane 20, and may assist in promoting capillary action and fluid flow through the membrane 20.
- the membrane 20 includes the collection region 30, which is the portion of the membrane disposed to receive the metered portion of the test sample from the sample meter 100.
- the collection region 30 collects and temporarily stores the test sample before the sample is conducted to a detection region 31 , as described in greater detail below.
- the sample meter 100 includes a separation membrane 110 at the filter section 106.
- This separation membrane 110 is selected from a known class of materials capable of filtering red blood cell components from fluids, examples of which are provided below.
- the sample meter 100 includes a storage membrane 112 disposed to receive filtered plasma or serum from the separation membrane 110.
- the separation membrane 110 and storage membrane 112 overlap along at least a portion of their length in an overlap region 114 depicted for example in Fig. 2B. In this overlap region 114, filtered plasma or serum is transferred from the separation membrane 110 to the storage membrane 112.
- the sample meter 100 or its constituent membrane components 110, 112, are not limited by dimensions or shape.
- the separation membrane 110 may have a length of between about 3 to about 12 mm.
- the overlap region 114 between the separation and storage membranes may be between about 1 mm to about 3 mm.
- the storage membrane 112 may have a length of between about 10 mm to about 40 mm.
- the sample meter 100 has the elongated strip shape illustrated in the figures with a width of between about 1 mm to about 5 mm, and a total length of between about 25 mm to about 40 mm.
- the separation membrane 110 may extend to the first end 102 of the meter 100, and the storage membrane 112 may extend to the opposite second end 104 of the meter 100.
- the storage membrane 112 may comprise any material through which test samples are capable of passing.
- the storage membrane 112 may be formed from any of the natural, synthetic, or naturally occurring materials identified above as suitable for use as membrane 20.
- a particularly useful material is a nitrocellulose membrane (e.g., Millipore Inc. HF 120 or 75).
- the separation membrane 110 may be any suitable material, for example, a hydrophobic material capable of filtering cells (e.g., blood cells) from fluids.
- a hydrophobic material capable of filtering cells (e.g., blood cells) from fluids.
- Various packings or sieving depth filters may be employed, such as glass fibers, cellulose or glass filters treated with red blood cell capture reagents, glass fiber filters, synthetic fiber filters or a composite material including any combination of the above materials.
- Glass fiber filters for instance, are commercially available from Whatman pic of Kent, United Kingdom; Millipore Corp. of Billerica, Massachusetts; and Pall Corp. of Ann Arbor, Michigan.
- Such glass fiber filters may have a fiber diameter in the range of about 0.05 to about 9 micrometers and a density of about 50 to about 150 g/m 2 .
- Other examples of suitable blood separation filters are described in U.S.
- the blood separation filter may be treated with one or more reagents (e.g., agglutinin), such as described above.
- a useful separation membrane is vertical blood separation membrane from PALL Inc. identified as "BTS SP 300.”
- this backing strip 116 is a generally transparent material so that migration of the blood plasma or serum to the storage section 108 of the meter 100 may be observed through the backing strip material 116.
- the sample meters 100 may be made with various processing steps.
- material such as Millipore nitrocellulose HF 75 or HF 120 may be laminated onto a transparent card material that serves as the backing strip 116.
- a separate piece of blood separation material serving as the separation membrane 110 may then be laminated onto the transparent card material with the desired overlap between it and the storage membrane material.
- the card with laminated materials may then be processed through a Kinematic slitter from Kinematic Automation, Inc., or other suitable cutting device, to cut the assembled card into strips having a desired width dimension (e.g. 1 mm, 2 mm, or so forth).
- a desired width dimension e.g. 1 mm, 2 mm, or so forth.
- the meter 100 may be inserted into a lateral flow assay device such that the storage section 108 lies adjacent to the membrane 20.
- This configuration is depicted generally in Fig. 1. Referring to Figs 4A and 4B, the sample meter 100 is inserted so as to lie above the membrane 20 from where it is subsequently pushed into contact with the membrane 20. In alternate embodiments, the sample meter 100 may lie below the membrane 20.
- the device 10 includes an internal scraping mechanism 40.
- the scraping mechanism 40 is configured to score and scrape the sample meter 100 so that a well defined length 66 (Fig. 6) of the sample meter is formed and presented to the collection region 30 of the test strip 18.
- the mechanism 40 scores the storage membrane 112 at locations that determine the length of the defined length section 66.
- the mechanism 40 scores the membrane 112 to the backing strip 116 and then "pushes" the margin portions 68 of the membrane 112 away from the defined length portion 66 so that the defined length portion 66 is no longer in fluid communication with the margin portions 68.
- the length of the defined length section 66 may be, for example, 5 mm, or any other desired length.
- the section 66 is saturated with the test sample fluid and, thus, based on the known saturation volume of the defined length section 66, a precisely determined amount of the test sample fluid is known and presented to the collection region 30 of the test strip 18.
- the mechanism 40 includes a pair of spaced apart and movably mounted blades 42.
- the blades 42 may be pivotally mounted relative to a common axis 44, as particularly illustrated in Figs. 4A and 4B.
- a first static position illustrated in Fig. 4A the blades 42 are disposed below the membrane surface side of the sample meter 100 and are spaced apart a distance that defines the length of the defined length section 66.
- a second actuated position illustrated for example in Fig. 4B the blades contact and score the membrane side of the sample member 100 as they pivot in opposite directions to scrape the side margins 68 away from the defined length section 66.
- the blades 42 may be mounted relative to the common longitudinal axis 44 on opposite longitudinal sides of the test strip 18, as particularly illustrated in Figs. 4A and 4B, and configured to rotate away from the test strip 18 in the second actuated position of the blades 42, as illustrated in Fig. 4B.
- the sample meter 100 may be disposed generally perpendicular to the test strip 18 so as to be disposed across the blades 42.
- Fig. 5 illustrates an internal tray 64 that may be configured to house the test strip 18 and blades 42.
- the test strip 18 is disposed longitudinally along the tray 64 between the blades 42.
- the sample meter 100 is depicted in phantom lines disposed above the blades 42 perpendicular to the test strip 18.
- test strip 18 is disposed below the sample meter 100 and a manually actuated device 46 is configured on the housing to move the blades 42 from their static position to the actuated position discussed above.
- This manually actuated device 46 may take on any suitable form, and may be, for example, a manual push or slide button 48 as illustrated in the figures.
- Motion of this button 48 may be transmitted to an internal plunger mechanism that pushes the sample meter 100 into contact with the blades 42, as illustrated in Figs. 4A and 4B. Transfer of motion from the button 48 to the plunger 50 may be achieved by any suitable means.
- the button 48 is a slide button that is moved along the surface of the housing 12.
- a cam track 54 is disposed on an underside of the button structure.
- a protrusion (not illustrated) of a component of the plunger 50 rides in the cam track 54, which causes the plunger 50 to move downward against the force of a biasing spring 52 as the plunger engages in the inclined cam slot 54.
- the plunger mechanism may include any manner of structure 56 that presses down on the sample meter 100, which causes the sample meter 100 to engage the blades 42 and to push the blades to their actuated position illustrated in Fig. 4B.
- the manual button 48 may be a type of button that is simply depressed in a vertical direction, resulting in structure 56 beneath the button engaging against the sample meter 100. It should be appreciated that any manner of manually actuated devices may be configured for the purpose of moving the sample meter 100 against the blades 42.
- Motion of the button 48 and associated plunger mechanism 50 also serves to press the defined length section 66 of the sample meter 100 against the collection region 30 of the underlying test strip 18.
- a diluent may be introduced, as described in greater detail below. During this transfer, however, it is generally desired to maintain the defined length section 66 in contact against the collection region of the test strip 18.
- any suitable latch mechanism 58 may be used to maintain the manually actuated device 46 (e.g., button 48) in a position that maintains the sample meter 100 against the test strip 18.
- a suitable latch mechanism 58 may include, for example, a spring loaded protrusion 60 provided on an underside of the slide button 48 that engages into a recess 62 defined in the upper surface of the housing 12, as schematically depicted in Figs. 3A and 3B. It should be appreciated that any manner of suitable latching or stop mechanism may be used in this regard. Regardless of the particular mechanism or method used to position and isolate a portion of the sample meter 100 relative to the membrane 20, a diluent (or washing agent) is generally employed upstream to facilitate delivery of the test sample from the storage section 108 of the meter 100 to the collection region 30 of the membrane 20.
- the diluent may be any material having a viscosity that is sufficiently low to allow movement of the fluid by capillary action and that supports a reaction between the analyte and any binding agents (e.g., does not interfere with antibody/antigen interaction).
- the diluent contains water, a buffering agent; a salt (e.g., NaCI); a protein stabilizer (e.g., BSA, casein, trehalose, or serum); and/or a detergent (e.g., nonionic surfactant).
- Representative buffering agents include, for example, phosphate-buffered saline (PBS) (e.g., pH of 7.2), 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3), HEPES buffer, TBS buffer, etc., and so forth.
- PBS phosphate-buffered saline
- MES 2-(N-morpholino) ethane sulfonic acid
- HEPES buffer e.g., pH of 5.3
- TBS buffer e.g., TBS buffer, etc.
- the assay device 10 may incorporate an internal source of diluent that is applied so as to flow to the collection region subsequent to insertion of the sample meter 100 into the assay housing 12 and scraping of the meter 100 to provide the defined length of meter.
- an internal diluent source is illustrated as a pouch or container 120 having the diluent contained therein.
- Means 134 are provided for rupturing or otherwise breaching the pouch 120 subsequent to or coincident with scraping of the sample meter 100.
- This means may be configured to operate simultaneously with the scraping mechanism 40, and may be actuated by the same manual button or slide 48.
- the means 134 includes a push button mechanism 138 or other manually actuated device that is readily configured with the assay housing 12.
- the pivotal blades 42 are configured so as to be pressed down onto the sample meter 100 upon the clinician activating the device 10 by pushing in the button 138.
- the pivotal blades 42 are brought into contact with the sample meter 100 and scrape the sample so as to define the metered length 66 of the sample meter 100, as well as pressing the sample meter into fluid contact with the underlying membrane 20.
- Points or a blade 136 may be provided on the push button mechanism 138 and disposed so as to pierce the internal pouch 120 causing the diluent to flow towards the collection region of the membrane 20.
- Sustained depression of the mechanism 138 may also serve to compress the pouch 120 and force the diluent therefrom in the direction of the collection region 30 of the membrane 20, as well as ensure that the sample meter 100 remains in contact with the membrane.
- a separate actuating device may be provided for rupturing the internal diluent source 120, such as a separate push button that is actuated after the scraping mechanism 40.
- a separate actuating device may be provided for rupturing the internal diluent source 120, such as a separate push button that is actuated after the scraping mechanism 40.
- an external diluent source 118 may be provided. In the illustrated embodiment, this external source is illustrated as a capsule 122 or other disposable container, preferably a squeezable container having a nozzle 124 configured for insertion into a port 126 defined in the assay housing 12.
- the port 126 is disposed so that the diluent is supplied upstream of the sample meter 100 and caused to flow towards the collection region of the membrane 20.
- Internal diluent directing structure such as channels or the like, may be defined within the housing 12 to more precisely direct the diluent to the desired location.
- the diagnostic test kit of the present invention may also contain various other components to enhance detection accuracy.
- various other components to enhance detection accuracy.
- an immunoassay that may be performed in accordance with the present invention to detect the presence of an analyte will now be described in more detail.
- Immunoassays utilize mechanisms of the immune systems, wherein antibodies are produced in response to the presence of antigens that are pathogenic or foreign to the organisms. These antibodies and antigens, i.e., immunoreactants, are capable of binding with one another, thereby causing a highly specific reaction mechanism that may be used to determine the presence or concentration of that particular antigen in a biological sample.
- a substance may be pre-applied to the sample meter 100, or previously mixed with the diluent or test sample, which is detectable either visually or by an instrumental device. Any substance generally capable of producing a signal that is detectable visually or by an instrumental device may be used as detection probes. Suitable detectable substances may include, for instance, luminescent compounds (e.g., fluorescent, phosphorescent, etc.); radioactive compounds; visual compounds (e.g., colored dye or metallic substance, such as gold); liposomes or other vesicles containing signal-producing substances; enzymes and/or substrates, and so forth. Other suitable detectable substances may be described in U.S. Patent Nos.
- the detectable substance is colored, the ideal electromagnetic radiation is light of a complementary wavelength. For instance, blue detection probes strongly absorb red light.
- the detectable substance may be a luminescent compound that produces an optically detectable signal.
- suitable fluorescent molecules may include, but are not limited to, fluorescein, europium chelates, phycobiliprotein, rhodamine, and their derivatives and analogs.
- Other suitable fluorescent compounds are semiconductor nanocrystals commonly referred to as "quantum dots.”
- such nanocrystals may contain a core of the formula CdX, wherein X is Se, Te, S, and so forth.
- the nanocrystals may also be passivated with an overlying shell of the formula YZ, wherein Y is Cd or Zn, and Z is S or Se.
- suitable semiconductor nanocrystals may also be described in U.S. Patent Nos. 6,261 ,779 to Barbera-Guillem, et al. and 6,585,939 to Dapprich, which are incorporated herein in their entirety by reference thereto for all purposes.
- suitable phosphorescent compounds may include metal complexes of one or more metals, such as ruthenium, osmium, rhenium, iridium, rhodium, platinum, indium, palladium, molybdenum, technetium, copper, iron, chromium, tungsten, zinc, and so forth.
- ruthenium, rhenium, osmium, platinum, and palladium are especially preferred.
- the metal complex may contain one or more ligands that facilitate the solubility of the complex in an aqueous or non-aqueous environment.
- ligands include, but are not limited to, pyridine; pyrazine; isonicotinamide; imidazole; bipyridine; terpyridine; phenanthroline; dipyridophenazine; porphyrin, porphine, and derivatives thereof.
- Such ligands may be, for instance, substituted with alky], substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, carboxylate, carboxaldehyde, carboxamide, cyano, amino, hydroxy, imino, hydroxycarbonyl, aminocarbonyl, amidine, guanidinium, ureide, sulfur-containing groups, phosphorus containing groups, and the carboxylate ester of N-hydroxy-succinimide.
- Porphyrins and porphine metal complexes possess pyrrole groups coupled together with methylene bridges to form cyclic structures with metal chelating inner cavities. Many of these molecules exhibit strong phosphorescence properties at room temperature in suitable solvents (e.g., water) and an oxygen-free environment.
- suitable porphyrin complexes that are capable of exhibiting phosphorescent properties include, but are not limited to, platinum (II) coproporphyrin-l and III, palladium (II) coproporphyrin, ruthenium coproporphyrin, zinc(ll)-coproporphyrin-l, derivatives thereof, and so forth.
- Bipyridine metal complexes may also be utilized as phosphorescent compounds.
- suitable bipyridine complexes include, but are note limited to, bisf ⁇ '-carbomethoxy ⁇ '-bipyridine] 2-[3-(4-methyl-2,2'- bipyridine-4-yl)propyl]-1 ,3-dioxolane ruthenium (II); bis(2,2'bipyridine)[4-(butan-1- alH'-methyl ⁇ '-bi-pyridinelruthenium (II); bis(2,2 I -bipyridine)[4-(4'-methyl-2,2 l - bipyridine-4'-yl)-butyric acid] ruthenium (II); tris(2,2'bipyridine)ruthenium (II); (2,2'- bipyridine) [bis-bis(1 ,2-diphenylphosphino)ethylene] 2-[3-(4-methyl-2,2'-bipyridine- 4'-
- luminescent compounds may have a relatively long emission lifetime may have a relatively large "Stokes shift.”
- the term “Stokes shift” is generally defined as the displacement of spectral lines or bands of luminescent radiation to a longer emission wavelength than the excitation lines or bands.
- a relatively large Stokes shift allows the excitation wavelength of a luminescent compound to remain far apart from its emission wavelengths and is desirable because a large difference between excitation and emission wavelengths makes it easier to eliminate the reflected excitation radiation from the emitted signal. Further, a large Stokes shift also minimizes interference from luminescent molecules in the sample and/or light scattering due to proteins or colloids, which are present with some body fluids (e.g., blood).
- the luminescent compounds have a Stokes shift of greater than about 50 nanometers, in some embodiments greater than about 100 nanometers, and in some embodiments, from about 100 to about 350 nanometers.
- exemplary fluorescent compounds having a large Stokes shift include lanthanide chelates of samarium (Sm (III)), dysprosium (Dy (III)), europium (Eu (III)), and terbium (Tb (III)). Such chelates may exhibit strongly red-shifted, narrow-band, long-lived emission after excitation of the chelate at substantially shorter wavelengths.
- the chelate possesses a strong ultraviolet excitation band due to a chromophore located close to the lanthanide in the molecule. Subsequent to excitation by the chromophore, the excitation energy may be transferred from the excited chromophore to the lanthanide. This is followed by a fluorescence emission characteristic of the lanthanide.
- Europium chelates for instance, have Stokes shifts of about 250 to about 350 nanometers, as compared to only about 28 nanometers for fluorescein. Also, the fluorescence of europium chelates is long-lived, with lifetimes of about 100 to about 1000 microseconds, as compared to about 1 to about 100 nanoseconds for other fluorescent labels.
- these chelates have a narrow emission spectra, typically having bandwidths less than about 10 nanometers at about 50% emission.
- One suitable europium chelate is N-(p-isothiocyanatobenzyl)-diethylene triamine tetraacetic acid-Eu +3 .
- lanthanide chelates that are inert, stable, and intrinsically fluorescent in aqueous solutions or suspensions may also be used in the present invention to negate the need for micelle-forming reagents, which are often used to protect chelates having limited solubility and quenching problems in aqueous solutions or suspensions.
- a chelate is 4-[2-(4- isothiocyanatophenyl)ethynyl]-2,6-bis([N,N-bis(carboxymethyl)amino]methyl)- pyridine [Ref: Lovgren, T., et al.; Clin. Chem. 42, 1196-1201 (1996)].
- lanthanide chelates also show exceptionally high signal-to-noise ratios.
- one such chelate is a tetradentate ⁇ -diketonate-europium chelate [Ref: Yuan, J. and Matsumoto, K.; Anal. Chem. 70, 596-601 (1998)].
- fluorescent labels described above, other labels that are suitable for use in the present invention may be described in U.S. Patent Nos.
- Detectable substances such as described above, may be used alone or in conjunction with a particle (sometimes referred to as "beads” or “microbeads”).
- a particle sometimes referred to as "beads” or “microbeads”
- naturally occurring particles such as nuclei, mycoplasma, plasmids, plastids, mammalian cells (e.g., erythrocyte ghosts), unicellular microorganisms (e.g., bacteria), polysaccharides (e.g., agarose), etc.
- synthetic particles may also be utilized.
- latex microparticles that are labeled with a fluorescent or colored dye are utilized.
- the particles are typically formed from polystyrene, butadiene styrenes, styreneacrylic-vinyl terpolymer, polymethylmethacrylate, polyethylmethacrylate, styrene-maleic anhydride copolymer, polyvinyl acetate, polyvinylpyridine, polydivinylbenzene, polybutyleneterephthalate, acrylonitrile, vinylchloride-acrylates, and so forth, or an aldehyde, carboxyl, amino, hydroxyl, or hydrazide derivative thereof.
- Other suitable particles may be described in U.S. Patent Nos.
- fluorescent particles include fluorescent carboxylated microspheres sold by Molecular Probes, Inc. under the trade names "FluoSphere” (Red 580/605) and “TransfluoSphere” (543/620), as well as "Texas Red” and 5- and 6-carboxytetramethylrhodamine, which are also sold by Molecular Probes, Inc.
- suitable colored, latex microparticles include carboxylated latex beads sold by Bang's Laboratory, Inc.
- Metallic particles e.g., gold particles may also be utilized in the present invention.
- the shape of the particles may generally vary.
- the particles are spherical in shape.
- other shapes are also contemplated by the present invention, such as plates, rods, discs, bars, tubes, irregular shapes, etc.
- the size of the particles may also vary.
- the average size (e.g., diameter) of the particles may range from about 0.1 nanometers to about 100 microns, in some embodiments, from about 1 nanometer to about 10 microns, and in some embodiments, from about 10 to about 100 nanometers.
- the detection probes may be modified with certain specific binding members that are adhered thereto to form conjugated probes.
- Specific binding members generally refer to a member of a specific binding pair, i.e., two different molecules where one of the molecules chemically and/or physically binds to the second molecule.
- immunoreactive specific binding members may include antigens, haptens, aptamers, antibodies (primary or secondary), and complexes thereof, including those formed by recombinant DNA methods or peptide synthesis.
- An antibody may be a monoclonal or polyclonal antibody, a recombinant protein or a mixture(s) or fragment(s) thereof, as well as a mixture of an antibody and other specific binding members.
- the details of the preparation of such antibodies and their suitability for use as specific binding members are well known to those skilled in the art.
- binding pairs include but are not limited to, biotin and avidin (or derivatives thereof), biotin and streptavidin, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, hormone and hormone binding protein, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and so forth.
- specific binding pairs may include members that are analogs of the original specific binding member. For example, a derivative or fragment of the analyte (i.e., "analog”) may be used so long as it has at least one epitope in common with the analyte.
- the specific binding members may generally be attached to the detection probes using any of a variety of well-known techniques. For instance, covalent attachment of the specific binding members to the detection probes (e.g., particles) may be accomplished using carboxylic, amino, aldehyde, bromoacetyl, iodoacetyl, thiol, epoxy and other reactive or linking functional groups, as well as residual free radicals and radical cations, through which a protein coupling reaction may be accomplished.
- a surface functional group may also be incorporated as a functionalized co-monomer because the surface of the detection probe may contain a relatively high surface concentration of polar groups.
- the detection probes may be capable of direct covalent linking with a protein without the need for further modification.
- the first step of conjugation is activation of carboxylic groups on the probe surface using carbodiimide.
- the activated carboxylic acid groups are reacted with an amino group of an antibody to form an amide bond.
- the activation and/or antibody coupling may occur in a buffer, such as phosphate-buffered saline (PBS) (e.g., pH of 7.2) or 2-(N-morpholino) ethane sulfonic acid (MES) (e.g., pH of 5.3).
- PBS phosphate-buffered saline
- MES 2-(N-morpholino) ethane sulfonic acid
- the resulting detection probes may then be contacted with ethanolamine, for instance, to block any remaining activated sites.
- this process forms a conjugated detection probe, where the antibody is covalently attached to the probe.
- other attachment techniques such as physical adsorption or chemisorption, may also be utilized in the present invention.
- the diluent and test sample travel through the membrane 20 until reaching the detection zone 31.
- the volume of the test sample is relatively uniform across the entire width of the detection zone 31.
- the volume of the test sample is also predetermined within a narrow range.
- a receptive material is immobilized that is capable of binding to the conjugated detection probes.
- the receptive material may be selected from the same materials as the specific binding members described above, including, for instance, antigens; haptens; antibody-binding proteins, such as protein A, protein G, or protein A/G; neutravidin (a deglycosylated avidin derivative), avidin (a highly cationic 66,000-dalton glycoprotein), streptavidin (a nonglycosylated 52,800-dalton protein), or captavidin (a nitrated avidin derivative); primary or secondary antibodies, and derivatives or fragments thereof.
- the receptive material is an antibody specific to an antigen within the test sample.
- the receptive material serves as a stationary binding site for complexes formed between the analyte and the conjugated detection probes.
- analytes such as antibodies, antigens, etc.
- analytes typically have two or more binding sites (e.g., epitopes).
- binding sites e.g., epitopes
- the free binding site of the analyte may bind to the immobilized first receptive material.
- the complexed probes form a new ternary sandwich complex.
- the membrane 20 may also define various other zones for enhancing detection accuracy.
- the assay device 20 may contain an indicator zone 33 that is positioned downstream from the detection zone 31 and is configured to provide information as to whether the analyte concentration has reached the saturation concentration ("hook effect" region) for the assay.
- the indicator zone 33 contains a second receptive material that is immobilized on the membrane 23 and serves as a stationary binding site for the conjugated detection probes. To accomplish the desired binding within the indicator zone 33, it is generally desired that the second receptive material is capable of differentiating between those detection probes that are complexed with the analyte and those that remain uncomplexed.
- the second receptive material includes a molecule that has at least one epitope in common with the analyte, such as analyte molecules, or derivatives or fragments (i.e., analog) thereof, so that it is capable of specifically binding to an antibody conjugate when it is uncomplexed with the analyte.
- the second receptive material may include a biological material that is not an analyte molecule or analog thereof, but nevertheless is capable of preferentially binding to uncomplexed conjugated detection probes.
- the first receptive material may be a monoclonal antibody, such as anti-CRP IgGi.
- the detection probes are conjugated with a monoclonal antibody different than the monoclonal antibody of the first receptive material, such as anti-CRP IgG 2 .
- the second receptive material may be a secondary antibody, such as Goat anti-human, IgG F(ab') 2 , which has been adsorbed against F c fragments and therefore reacts only with the F ab portion of IgG.
- the secondary antibody is able to bind to the free "F at> " binding domain of the anti-CRP lgG2 monoclonal antibody.
- an antigen when present in the test sample, it first complexes with the "F at> " binding domain of the anti-CRP IgG 2 monoclonal antibody. The presence of the antigen renders the "F at> " binding domain unavailable for subsequent binding with the secondary antibody. In this manner, the secondary antibody within the indicator zone 33 is capable of preferentially binding to uncomplexed detection probes.
- the test strip 18 may include a calibration zone 32 that is positioned downstream from the detection zone 31 and optional indicator zone 33.
- the calibration zone 32 may also be positioned upstream from the detection zone 31 and/or optional indicator zone 33.
- the calibration zone 32 is provided with a third receptive material that is capable of binding to any calibration probes that pass through the length of the membrane 20.
- the calibration probes may contain a detectable substance that is the same or different than the detectable substance used for the detection probes.
- the calibration probes may also be conjugated with a specific binding member, such as described above.
- biotinylated calibration probes may be used.
- the calibration probes are selected in such a manner that they do not bind to the first or second receptive material at the detection zone 31 and indicator zone 33.
- the third receptive material of the calibration zone 32 may be the same or different than the receptive materials used in the detection zone 31 or indicator zone 33.
- the third receptive material is a biological receptive material, such as antigens, haptens, antibody-binding proteins (e.g., protein A, protein G, or protein A/G), neutravidin, avidin, streptavidin, captavidin, primary or secondary antibodies, or complexes thereof.
- the third receptive material e.g., polyelectrolytes
- the polyelectrolytes may have a net positive or negative charge, as well as a net charge that is generally neutral.
- polyelectrolytes having a net positive charge include, but are not limited to, polylysine (commercially available from Sigma-Aldrich Chemical Co., Inc. of St.
- CelQuat® SC-230M or H-100 available from National Starch & Chemical, Inc., which are cellulosic derivatives containing a quaternary ammonium water-soluble monomer, may be utilized.
- polyelectrolytes having a net negative charge include, but are not limited to, polyacrylic acids, such as poly(ethylene-co-methacrylic acid, sodium salt), and so forth. It should also be understood that other polyelectrolytes may also be utilized, such as amphiphilic polyelectrolytes (i.e., having polar and non- polar portions). For instance, some examples of suitable amphiphilic polyelectrolytes include, but are not limited to, poly(styryl-b-N-methyl 2-vinyl pyridnium iodide) and poly(styryl-b-acrylic acid), both of which are available from Polymer Source, Inc. of Dorval, Canada.
- the polyelectrolyte selected for a particular application may vary depending on the nature of the detection probes, the calibration probes, the membrane, and so forth.
- the distributed charge of a polyelectrolyte allows it to bind to substances having an opposite charge.
- polyelectrolytes having a net positive charge are often better equipped to bind with probes that are negatively charged, while polyelectrolytes that have a net negative charge are often better equipped to bind to probes that are positively charged.
- the ionic interaction between these molecules allows the required binding to occur within the calibration zone 32.
- polyelectrolytes may also bind with probes having a similar charge. Because the polyelectrolyte is designed to bind to probes, it is typically desired that the polyelectrolyte be substantially non-diffusively immobilized on the surface of the membrane 20. Otherwise, the probes would not be readily detectable by a user. Thus, the polyelectrolytes may be applied to the membrane 20 in such a manner that they do not substantially diffuse into the matrix of the membrane 20. In particular, the polyelectrolytes typically form an ionic and/or covalent bond with functional groups present on the surface of the membrane 20 so that they remain immobilized thereon.
- the formation of covalent bonds between the polyelectrolyte and the membrane 20 may be desired to more permanently immobilize the poiyelectrolyte thereon.
- the monomers used to form the polyelectrolyte are first formed into a solution and then applied directly to the membrane 23.
- Various solvents e.g., organic solvents, water, etc.
- the polymerization of the monomers is initiated using heat, electron beam radiation, free radical polymerization, and so forth.
- the monomers polymerize, they form covalent bonds with certain functional groups of the membrane 20, thereby immobilizing the resulting polyelectrolyte thereon.
- an ethyleneimine monomer may form a covalent bond with a carboxyl group present on the surface of some membranes (e.g., nitrocellulose).
- the polyelectrolyte may be formed prior to application to the membrane 20. If desired, the polyelectrolyte may first be formed into a solution using organic solvents, water, and so forth. Thereafter, the polyelectrolytic solution is applied directly to the membrane 20 and then dried. Upon drying, the polyelectrolyte may form an ionic bond with certain functional groups present on the surface of the membrane 20 that have a charge opposite to the polyelectrolyte. For example, in one embodiment, positively-charged polyethyleneimine may form an ionic bond with negatively-charged carboxyl groups present on the surface of some membranes (e.g., nitrocellulose).
- some membranes e.g., nitrocellulose
- polyelectrolyte may also be crosslinked to the membrane 23 using various well-known techniques.
- epichlorohydrin-functionalized polyamines and/or polyamidoamines may be used as a crosslinkable, positively-charged polyelectrolyte. Examples of these materials are described in U.S. Pat. Nos. 3,700,623 to Keim and 3,772,076 to Keim, 4,537,657 to Keim, which are incorporated herein in their entirety by reference thereto for all purposes and are believed to be sold by Hercules, Inc., Wilmington, Del. under the KymeneTM trade designation.
- KymeneTM 450 and 2064 are epichlorohydrin-functionalized polyamine and/or polyamidoamine compounds that contain epoxide rings and quaternary ammonium groups that may form covalent bonds with carboxyl groups present on certain types of membranes (e.g., nitrocellulose) and crosslink with the polymer backbone of the membrane when cured.
- the crosslinking temperature may range from about 50°C to about 120 0 C and the crosslinking time may range from about 10 to about 600 seconds.
- any other technique for non-diffusively immobilizing polyelectrolytic compounds may be used in the present invention.
- the aforementioned methods are only intended to be exemplary of the techniques that may be used in the present invention.
- certain components may be added to the polyelectrolyte solution that may substantially inhibit the diffusion of such polyelectrolytes into the matrix of the membrane 20.
- the detection zone 31 , indicator zone 33, and calibration zone 32 may each provide any number of distinct detection regions so that a user may better determine the concentration of one or more analytes within a test sample.
- Each region may contain the same receptive materials, or may contain different receptive materials.
- the zones may include two or more distinct regions (e.g., lines, dots, etc.).
- the regions may be disposed in the form of lines in a direction that is substantially perpendicular to the flow of the test sample through the test strip 18.
- the regions may be disposed in the form of lines in a direction that is substantially parallel to the flow of the test sample.
- the membrane 20 may also define a control zone (not shown) that gives a signal to the user that the assay is performing properly.
- control zone may contain an immobilized receptive material that is generally capable of forming a chemical and/or physical bond withprobes or with the receptive material immobilized on the probes.
- receptive materials include, but are not limited to, antigens, haptens, antibodies, protein A or G, avidin, streptavidin, secondary antibodies, and complexes thereof.
- control zone receptive material may also include a polyelectrolyte, such as described above, that may bind to uncaptured probes.
- control zone may be positioned at any location along the membrane 20, but is preferably positioned downstream from the detection zone 31 and the indicator zone 33.
- the intensity of any signals produced at the detection zone 31 , indicator zone 33, and/or calibration zone 32 may be measured with an optical reader.
- the actual configuration and structure of the optical reader may generally vary as is readily understood by those skilled in the art.
- optical detection techniques include, but are not limited to, luminescence (e.g., fluorescence, phosphorescence, etc.), absorbance (e.g., fluorescent or non-fluorescent), diffraction, etc.
- luminescence e.g., fluorescence, phosphorescence, etc.
- absorbance e.g., fluorescent or non-fluorescent
- diffraction etc.
- One suitable reflectance spectrophotometer is described, for instance, in U.S. Patent App. Pub. No.
- a reflectance-mode spectrofluorometer may be used to detect the intensity of a fluorescence signal. Suitable spectrofluorometers and related detection techniques are described, for instance, in U.S. Patent App. Pub. No. 2004/0043502 to Song, et al., which is incorporated herein in its entirety by reference thereto for all purposes.
- a transmission-mode detection system may also be used to signal intensity.
- a "sandwich” format typically involves mixing the test sample with detection probes conjugated with a specific binding member (e.g., antibody) for the analyte to form complexes between the analyte and the conjugated probes. These complexes are then allowed to contact a receptive material (e.g., antibodies) immobilized within the detection zone. Binding occurs between the analyte/probe conjugate complexes and the immobilized receptive material, thereby localizing "sandwich” complexes that are detectable to indicate the presence of the analyte.
- a specific binding member e.g., antibody
- This technique may be used to obtain quantitative or semi-quantitative results.
- sandwich-type assays are described by U.S. Patent Nos. 4,168,146 to Grubb, et al. and 4,366,241 to Tom, et al., which are incorporated herein in their entirety by reference thereto for all purposes.
- the labeled probe is generally conjugated with a molecule that is identical to, or an analog of, the analyte.
- the labeled probe competes with the analyte of interest for the available receptive material.
- Competitive assays are typically used for detection of analytes such as haptens, each hapten being monovalent and capable of binding only one antibody molecule.
- a controlled volume of a test sample may be uniformly delivered to a detection zone of a lateral flow assay device.
- Such control over sample flow provides a significant improvement in detection accuracy and sensitivity for lateral flow systems.
- sample application and testing may be done in a relatively quick, easy, and simple manner.
- low volume test samples may be accurately tested without the requirement of complex and expensive equipment to obtain a useable sample. For example, whole blood drops having a volume of about 5 microliters or less may be readily analyzed for the presence of an analyte in accordance with the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ecology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009540894A JP2010513854A (en) | 2006-12-15 | 2007-08-23 | Lateral flow assay device |
EP07826115.3A EP2088929B1 (en) | 2006-12-15 | 2007-08-23 | Lateral flow assay device |
CN2007800450406A CN101547641B (en) | 2006-12-15 | 2007-08-23 | Lateral flow assay device |
CA002670564A CA2670564A1 (en) | 2006-12-15 | 2007-08-23 | Lateral flow assay device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/640,435 US8377379B2 (en) | 2006-12-15 | 2006-12-15 | Lateral flow assay device |
US11/640,435 | 2006-12-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008075213A2 true WO2008075213A2 (en) | 2008-06-26 |
WO2008075213A3 WO2008075213A3 (en) | 2009-02-19 |
Family
ID=39527477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2007/053381 WO2008075213A2 (en) | 2006-12-15 | 2007-08-23 | Lateral flow assay device |
Country Status (7)
Country | Link |
---|---|
US (1) | US8377379B2 (en) |
EP (1) | EP2088929B1 (en) |
JP (1) | JP2010513854A (en) |
KR (1) | KR20090089398A (en) |
CN (1) | CN101547641B (en) |
CA (1) | CA2670564A1 (en) |
WO (1) | WO2008075213A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012510623A (en) * | 2008-12-03 | 2012-05-10 | エフ.ホフマン−ラ ロシュ アーゲー | Test element with combined control and calibration zone |
CN103027693A (en) * | 2011-10-05 | 2013-04-10 | 生物梅里埃公司 | Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly |
DE202012101167U1 (en) * | 2012-03-30 | 2013-07-01 | Seramun Diagnostica Gmbh | Apparatus for determining samples in a sample volume assembly and stator for the apparatus |
US9046518B2 (en) | 2009-04-09 | 2015-06-02 | Hitachi Chemical Company, Ltd. | Detector and detection method |
US9783844B2 (en) | 2012-04-27 | 2017-10-10 | Kaneka Corporation | Method for amplifying nucleic acid and method for detecting amplified nucleic acid |
US9920356B2 (en) | 2010-11-24 | 2018-03-20 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
US10392652B2 (en) | 2013-11-22 | 2019-08-27 | Kaneka Corporation | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end |
US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
FR3119023A1 (en) * | 2021-01-21 | 2022-07-22 | Ng Biotech | System for rapid analysis of a capillary blood sample from a subject, intended to detect the presence of at least one analyte in said capillary blood sample |
US11740181B2 (en) | 2017-12-13 | 2023-08-29 | Bloom Diagnostics Ag | Preparation device, diagnostic apparatus, diagnostic kit and diagnostic system |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090048576A1 (en) * | 2007-08-13 | 2009-02-19 | Mark Ries Robinson | Managing Cross-contamination in Blood Samples Withdrawn from a Multilumen Catheter |
US8562917B2 (en) * | 2008-08-20 | 2013-10-22 | Bayer Healthcare Llc | Analyte meter sleeves and methods |
EP2375249B1 (en) * | 2010-04-09 | 2019-12-25 | F. Hoffmann-La Roche AG | Devices and process for separating plasma from a blood sample |
US8920857B2 (en) | 2010-12-22 | 2014-12-30 | Michael T. Abramson | System and method for detection of a contaminated beverage |
US9285352B2 (en) | 2010-12-22 | 2016-03-15 | Drinksavvy, Inc. | System and method for detection of a contaminated beverage |
EP2802260B1 (en) * | 2012-01-10 | 2015-12-09 | Sanofi-Aventis Deutschland GmbH | An apparatus for eliciting a blood sample |
MX364399B (en) | 2012-04-03 | 2019-04-25 | Redxdefense Llc | SYSTEM and METHOD FOR OPTICAL DETECTION USING CAPILLARY ACTION. |
CN103575889B (en) * | 2012-08-03 | 2016-04-20 | 北京勤邦生物技术有限公司 | A kind of test strips and method detecting vancomycin |
RU2698311C2 (en) * | 2014-03-20 | 2019-08-26 | Байо-Ред Лабораториз, Инк. | Analysis for glycated proteins |
US9568404B2 (en) | 2014-05-16 | 2017-02-14 | Junyu Mai | Method and apparatus for biomolecule analysis |
JP6397939B2 (en) | 2014-06-09 | 2018-09-26 | スリーエム イノベイティブ プロパティズ カンパニー | Assay apparatus and target analyte detection method |
WO2016040697A1 (en) * | 2014-09-10 | 2016-03-17 | Quantumdx Group Limited | Sorbent material for separating bio-macromolecules |
JP6385245B2 (en) * | 2014-11-04 | 2018-09-05 | Nissha株式会社 | Detection apparatus and detection method |
GB2535998A (en) * | 2015-02-27 | 2016-09-07 | Intelligent Fingerprinting Ltd | A device for receiving and analysing a sample |
US9995743B2 (en) * | 2015-07-01 | 2018-06-12 | Htc Corporation | Test apparatus and pressurizing assembly thereof |
CN105445454B (en) * | 2015-11-20 | 2016-11-30 | 广州瑞博奥生物科技有限公司 | A kind of can be quantitative device for immunochromatography |
JP7252899B2 (en) * | 2016-12-01 | 2023-04-05 | ノベル マイクロデバイシズ,インク. | Automated point-of-care device and method of use for complex sample processing |
WO2018129056A1 (en) | 2017-01-04 | 2018-07-12 | The Research Foundation For The State University Of New York | Biomarker detection device |
WO2018128749A1 (en) * | 2017-01-06 | 2018-07-12 | Dnt Scientific Research, Llc | Rapid diagnostic test device by driven flow technology |
US11630106B2 (en) | 2017-05-19 | 2023-04-18 | Philip Morris Products S.A. | Diagnostic test for distinguishing the smoking status of a subject |
WO2019152657A1 (en) | 2018-02-03 | 2019-08-08 | Simple Healthkit, Inc. | Reliable, comprehensive, and rapid sexual health assessment |
DE102018000965A1 (en) * | 2018-02-07 | 2019-08-08 | Lilian Labs GmbH | Apparatus and method for liquid analysis |
JP2022509817A (en) * | 2018-11-28 | 2022-01-24 | ウィーブル ヘルス コープ. | Simultaneous spot inspection and storage of blood samples |
KR102660008B1 (en) * | 2021-10-08 | 2024-04-23 | 한국과학기술원 | Liquid Suction Device for Lateral Flow Assay Using Movable Button with Absorbent Paper |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US5075077A (en) | 1988-08-02 | 1991-12-24 | Abbott Laboratories | Test card for performing assays |
US5252459A (en) | 1988-09-23 | 1993-10-12 | Abbott Laboratories | Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles |
US5416000A (en) | 1989-03-16 | 1995-05-16 | Chemtrak, Inc. | Analyte immunoassay in self-contained apparatus |
US5423989A (en) | 1988-05-19 | 1995-06-13 | Chemtrack, Inc. | Plasma forming device |
US5670381A (en) | 1988-01-29 | 1997-09-23 | Abbott Laboratories | Devices for performing ion-capture binding assays |
US6436651B1 (en) | 1997-12-16 | 2002-08-20 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
US6585939B1 (en) | 1999-02-26 | 2003-07-01 | Orchid Biosciences, Inc. | Microstructures for use in biological assays and reactions |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622871A (en) | 1987-04-27 | 1997-04-22 | Unilever Patent Holdings B.V. | Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents |
EP0146654A3 (en) | 1980-06-20 | 1986-08-20 | Unilever Plc | Processes and apparatus for carrying out specific binding assays |
US4503856A (en) | 1981-06-29 | 1985-03-12 | Sherwood Medical Company | Lancet injector |
US4517978A (en) | 1983-01-13 | 1985-05-21 | Levin Paul D | Blood sampling instrument |
GB8406752D0 (en) | 1984-03-15 | 1984-04-18 | Unilever Plc | Chemical and clinical tests |
US4743560A (en) | 1984-03-26 | 1988-05-10 | Becton Dickinson And Company | Solid phase assay |
TW203120B (en) | 1985-10-04 | 1993-04-01 | Abbott Lab | |
US4835099A (en) | 1986-11-20 | 1989-05-30 | Becton, Dickinson And Company | Signal enhancement in immunoassay by modulation of enzymatic catalysis |
US4954435A (en) | 1987-01-12 | 1990-09-04 | Becton, Dickinson And Company | Indirect colorimetric detection of an analyte in a sample using ratio of light signals |
US4920046A (en) | 1987-02-20 | 1990-04-24 | Becton, Dickinson And Company | Process, test device, and test kit for a rapid assay having a visible readout |
USRE38430E1 (en) | 1987-03-27 | 2004-02-17 | Becton, Dickinson And Company | Solid phase chromatographic immunoassay |
CA1303983C (en) | 1987-03-27 | 1992-06-23 | Robert W. Rosenstein | Solid phase assay |
JPH0684970B2 (en) * | 1987-03-31 | 1994-10-26 | 株式会社京都医科学研究所 | Method of detecting occult blood in feces |
GB2204398B (en) | 1987-04-27 | 1991-08-28 | Unilever Plc | Analytical test device for use in assays |
US4904583A (en) | 1987-05-26 | 1990-02-27 | Becton, Dickinson And Company | Cascade immunoassay by multiple binding reactions |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US4956302A (en) | 1987-09-11 | 1990-09-11 | Abbott Laboratories | Lateral flow chromatographic binding assay device |
US5073340A (en) | 1987-10-08 | 1991-12-17 | Becton, Dickinson And Company | Depositing a binder on a solid support |
US4978625A (en) | 1987-10-19 | 1990-12-18 | Becton, Dickinson And Company | Fluorescence immunoassay using water insoluble dyes |
US5275785A (en) | 1987-10-30 | 1994-01-04 | Unilever Patent Holdings B.V. | Test device for detecting an analyte in a liquid sample |
US5573919A (en) | 1988-06-02 | 1996-11-12 | Carter-Wallace | Assay using an absorbent material |
AU2684488A (en) | 1988-06-27 | 1990-01-04 | Carter-Wallace, Inc. | Test device and method for colored particle immunoassay |
US5208143A (en) | 1988-11-17 | 1993-05-04 | Becton, Dickinson And Company | Immunoassay on a preblocked solid surface |
US6352862B1 (en) | 1989-02-17 | 2002-03-05 | Unilever Patent Holdings B.V. | Analytical test device for imuno assays and methods of using same |
US5185127A (en) | 1989-09-21 | 1993-02-09 | Becton, Dickinson And Company | Test device including flow control means |
US5075078A (en) | 1989-10-05 | 1991-12-24 | Abbott Laboratories | Self-performing immunochromatographic device |
US6274324B1 (en) | 1989-12-01 | 2001-08-14 | Unilever Patent Holdings B.V. | Specific binding reagent comprising a variable domain protein linked to a support or tracer |
US5428690A (en) | 1991-09-23 | 1995-06-27 | Becton Dickinson And Company | Method and apparatus for automated assay of biological specimens |
JP2572823Y2 (en) | 1992-02-13 | 1998-05-25 | 株式会社アドバンス | Simple blood sampler |
GB9207120D0 (en) | 1992-04-01 | 1992-05-13 | Owen Mumford Ltd | Improvements relating to blood sampling devices |
JP2630197B2 (en) | 1993-04-28 | 1997-07-16 | 株式会社ニッショー | Blood suction device |
US5415994A (en) * | 1993-08-02 | 1995-05-16 | Quidel Corporation | Lateral flow medical diagnostic assay device with sample extraction means |
GB9419267D0 (en) | 1994-09-23 | 1994-11-09 | Unilever Plc | Assay devices |
DE69530315T2 (en) | 1994-11-24 | 2004-02-12 | Inverness Medical Switzerland Gmbh | RECOVERY AND USE OF SPECIFIC BINDING REAGENTS |
GB9505425D0 (en) | 1995-03-17 | 1995-05-03 | Unilever Plc | Assay devices |
EP0832430B1 (en) | 1995-05-09 | 2006-07-26 | Beckman Coulter, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US5788863A (en) | 1995-12-13 | 1998-08-04 | Becton Dickinson And Company | Apparatus and method for conducting an assay using reverse flow through a membrane |
US5662127A (en) | 1996-01-17 | 1997-09-02 | Bio-Plas, Inc. | Self-contained blood withdrawal apparatus and method |
US5945281A (en) | 1996-02-02 | 1999-08-31 | Becton, Dickinson And Company | Method and apparatus for determining an analyte from a sample fluid |
US5951493A (en) | 1997-05-16 | 1999-09-14 | Mercury Diagnostics, Inc. | Methods and apparatus for expressing body fluid from an incision |
CA2254108C (en) | 1996-05-23 | 2008-07-22 | Unilever Plc | Improvements in or relating to specific binding assays |
US6194220B1 (en) | 1996-09-25 | 2001-02-27 | Becton, Dickinson And Company | Non-instrumented assay with quantitative and qualitative results |
US5798273A (en) | 1996-09-25 | 1998-08-25 | Becton Dickinson And Company | Direct read lateral flow assay for small analytes |
US5998221A (en) | 1996-09-25 | 1999-12-07 | Becton, Dickinson And Company | Non-instrumented assay with quantitative and qualitative results |
DE69624920T2 (en) | 1996-09-27 | 2003-09-18 | Inverness Medical Switzerland Gmbh, Zug | Test reagents and test devices |
EP0833145B1 (en) | 1996-09-27 | 2003-01-29 | Inverness Medical Switzerland GmbH | Test kit and devices |
PT833158E (en) | 1996-09-27 | 2002-05-31 | Unilever Nv | MANUFACTURE OF TEST STRIPS |
US6093156A (en) | 1996-12-06 | 2000-07-25 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
US6057165A (en) | 1997-02-07 | 2000-05-02 | Becton, Dickinson And Company | Quality control procedure for membrane flow-through diagnostic assay devices |
GB2322192B (en) | 1997-02-14 | 2001-01-31 | Unilever Plc | Assay devices |
US5989924A (en) | 1997-09-30 | 1999-11-23 | Becton, Dickinson And Company | Device for determining an analyte in a sample |
US6077669A (en) | 1997-11-04 | 2000-06-20 | Becton Dickinson And Company | Kit and method for fluorescence based detection assay |
DE19811622A1 (en) | 1998-03-17 | 1999-09-23 | Lre Technology Partner Gmbh | Laboratory instrument incorporating split test card housing |
GB9807134D0 (en) | 1998-04-02 | 1998-06-03 | Unilever Plc | Test methods devices and test kits |
US6140136A (en) | 1998-09-18 | 2000-10-31 | Syntron Bioresearch, Inc. | Analytical test device and method of use |
JP2001349892A (en) | 2000-04-03 | 2001-12-21 | Unilever Nv | Test method and device |
CA2342683A1 (en) | 2000-04-03 | 2001-10-03 | Unilever Plc | Test methods and devices |
US6627459B1 (en) | 2000-04-19 | 2003-09-30 | Applied Biotech, Inc. | Immunoassay controls |
GB2365526B (en) | 2000-07-31 | 2003-12-03 | Cambridge Life Sciences | Assay apparatus for measuring the amount of an analyte in a biological or environmental sample |
US7052831B2 (en) | 2000-09-29 | 2006-05-30 | Becton Dickinson And Company | Detection of multiple analytes from a single sample using a multi-well, multi-analyte flow-through diagnostic test device |
US6653149B1 (en) | 2000-10-16 | 2003-11-25 | Applied Biotech Inc. | Specimen collection device and method |
US6524864B2 (en) | 2000-12-28 | 2003-02-25 | Aurora L. Fernandez Decastro | Test strip for simultaneous detection of a plurality of analytes |
US6669908B2 (en) | 2001-07-25 | 2003-12-30 | Applied Biotech, Inc. | Urine test device |
AU2002360205A1 (en) | 2001-12-27 | 2003-07-30 | Inverness Medical Switzerland Gmbh | System and method for fluorescence detection |
US7303726B2 (en) * | 2002-05-09 | 2007-12-04 | Lifescan, Inc. | Minimal procedure analyte test system |
AU2003240145A1 (en) | 2002-06-27 | 2004-01-19 | Unipath Limited | Assay reader |
GB2391813B (en) | 2002-08-14 | 2006-03-29 | Cozart Bioscience Ltd | An oral fluid collection, transfer and transportation device and method |
US7459314B2 (en) | 2003-02-13 | 2008-12-02 | Inverness Medical Switzerland Gmbh | Lateral flow immunoassay controls |
US7239394B2 (en) | 2003-06-04 | 2007-07-03 | Inverness Medical Switzerland Gmbh | Early determination of assay results |
US7315378B2 (en) | 2003-06-04 | 2008-01-01 | Inverness Medical Switzerland Gmbh | Optical arrangement for assay reading device |
JP2005056604A (en) | 2003-08-06 | 2005-03-03 | Hitachi Displays Ltd | Self-luminous flat display device |
JP2007524844A (en) | 2003-09-22 | 2007-08-30 | ベクトン・ディキンソン・アンド・カンパニー | Quantification of biomolecular analytes by mass spectrometry using a dendrimer internal standard |
US7090803B1 (en) | 2003-10-28 | 2006-08-15 | American Bio Medica Corporation | Lateral flow immunoassay device |
US7662562B2 (en) | 2004-08-10 | 2010-02-16 | Becton, Dickinson And Company | Method for rapid identification of microorganisms |
WO2006104962A1 (en) | 2005-03-28 | 2006-10-05 | Becton, Dickinson And Company | An improved system and method for stirring suspended solids in liquid media |
US20060240569A1 (en) | 2005-04-20 | 2006-10-26 | Becton, Dickinson And Company | Semi-quantitative immunochromatographic device |
US7618810B2 (en) * | 2005-12-14 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Metering strip and method for lateral flow assay devices |
-
2006
- 2006-12-15 US US11/640,435 patent/US8377379B2/en active Active
-
2007
- 2007-08-23 KR KR1020097012081A patent/KR20090089398A/en not_active Application Discontinuation
- 2007-08-23 JP JP2009540894A patent/JP2010513854A/en active Pending
- 2007-08-23 CA CA002670564A patent/CA2670564A1/en not_active Abandoned
- 2007-08-23 CN CN2007800450406A patent/CN101547641B/en active Active
- 2007-08-23 EP EP07826115.3A patent/EP2088929B1/en active Active
- 2007-08-23 WO PCT/IB2007/053381 patent/WO2008075213A2/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4366241B1 (en) | 1980-08-07 | 1988-10-18 | ||
US5670381A (en) | 1988-01-29 | 1997-09-23 | Abbott Laboratories | Devices for performing ion-capture binding assays |
US5423989A (en) | 1988-05-19 | 1995-06-13 | Chemtrack, Inc. | Plasma forming device |
US5075077A (en) | 1988-08-02 | 1991-12-24 | Abbott Laboratories | Test card for performing assays |
US5252459A (en) | 1988-09-23 | 1993-10-12 | Abbott Laboratories | Indicator reagents, diagnostic assays and test kits employing organic polymer latex particles |
US5416000A (en) | 1989-03-16 | 1995-05-16 | Chemtrak, Inc. | Analyte immunoassay in self-contained apparatus |
US6436651B1 (en) | 1997-12-16 | 2002-08-20 | Kimberly-Clark Worldwide, Inc. | Optical diffraction biosensor |
US6585939B1 (en) | 1999-02-26 | 2003-07-01 | Orchid Biosciences, Inc. | Microstructures for use in biological assays and reactions |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012510623A (en) * | 2008-12-03 | 2012-05-10 | エフ.ホフマン−ラ ロシュ アーゲー | Test element with combined control and calibration zone |
US9046518B2 (en) | 2009-04-09 | 2015-06-02 | Hitachi Chemical Company, Ltd. | Detector and detection method |
US9920356B2 (en) | 2010-11-24 | 2018-03-20 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
US10829805B2 (en) | 2010-11-24 | 2020-11-10 | Kaneka Corporation | Amplified nucleic acid detection method and detection device |
CN103027693A (en) * | 2011-10-05 | 2013-04-10 | 生物梅里埃公司 | Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly |
WO2013050701A1 (en) * | 2011-10-05 | 2013-04-11 | bioMérieux | Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly |
FR2981163A1 (en) * | 2011-10-05 | 2013-04-12 | Biomerieux Sa | ASSEMBLY FOR DETERMINING THE PRESENCE OR ABSENCE OF AN ANALYTE IN A BLOOD SAMPLE AND ANALYTICAL UNIT COMPRISING SUCH AN ASSEMBLY |
US9480428B2 (en) | 2011-10-05 | 2016-11-01 | Biomerieux | Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly |
EP3321685A1 (en) * | 2011-10-05 | 2018-05-16 | bioMérieux | Assembly for determining the presence or absence of an analyte in a blood sample and analysis unit comprising such an assembly |
WO2013143533A1 (en) | 2012-03-30 | 2013-10-03 | Seramun Diagnostica Gmbh | Device for identifying samples in a sample arrangement and stand for the device |
DE202012101167U1 (en) * | 2012-03-30 | 2013-07-01 | Seramun Diagnostica Gmbh | Apparatus for determining samples in a sample volume assembly and stator for the apparatus |
US9783844B2 (en) | 2012-04-27 | 2017-10-10 | Kaneka Corporation | Method for amplifying nucleic acid and method for detecting amplified nucleic acid |
US10392652B2 (en) | 2013-11-22 | 2019-08-27 | Kaneka Corporation | Micro RNA detection method using two primers to produce an amplified double stranded DNA fragment having a single stranded region at one end |
US11266337B2 (en) | 2015-09-09 | 2022-03-08 | Drawbridge Health, Inc. | Systems, methods, and devices for sample collection, stabilization and preservation |
US10638963B2 (en) | 2017-01-10 | 2020-05-05 | Drawbridge Health, Inc. | Devices, systems, and methods for sample collection |
US10888259B2 (en) | 2017-01-10 | 2021-01-12 | Drawbridge Health, Inc. | Cartridge assemblies for storing biological samples |
US10932710B2 (en) | 2017-01-10 | 2021-03-02 | Drawbridge Health, Inc. | Carriers for storage and transport of biological samples |
US11298060B2 (en) | 2017-01-10 | 2022-04-12 | Drawbridge Health, Inc. | Devices for collecting biological samples |
US11740181B2 (en) | 2017-12-13 | 2023-08-29 | Bloom Diagnostics Ag | Preparation device, diagnostic apparatus, diagnostic kit and diagnostic system |
FR3119023A1 (en) * | 2021-01-21 | 2022-07-22 | Ng Biotech | System for rapid analysis of a capillary blood sample from a subject, intended to detect the presence of at least one analyte in said capillary blood sample |
WO2022157256A1 (en) * | 2021-01-21 | 2022-07-28 | Ng Biotech | System for rapid analysis of a capillary blood sample from a subject, for detecting the presence of at least one analyte in said capillary blood sample |
Also Published As
Publication number | Publication date |
---|---|
JP2010513854A (en) | 2010-04-30 |
CN101547641B (en) | 2013-06-12 |
EP2088929A2 (en) | 2009-08-19 |
CA2670564A1 (en) | 2008-06-26 |
US20080145272A1 (en) | 2008-06-19 |
US8377379B2 (en) | 2013-02-19 |
CN101547641A (en) | 2009-09-30 |
WO2008075213A3 (en) | 2009-02-19 |
EP2088929B1 (en) | 2017-06-21 |
KR20090089398A (en) | 2009-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8377379B2 (en) | Lateral flow assay device | |
US8124421B2 (en) | Flow control technique for assay devices | |
US7618810B2 (en) | Metering strip and method for lateral flow assay devices | |
EP1875241B1 (en) | Metering technique for lateral flow assay devices | |
EP1960782B1 (en) | Metering technique for lateral flow assay devices | |
KR101288296B1 (en) | Assay devices having detection capabilities within the hook effect region | |
US7713748B2 (en) | Method of reducing the sensitivity of assay devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780045040.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07826115 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2670564 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2007826115 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007826115 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097012081 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2009540894 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3403/CHENP/2009 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |